On April 4, 2017 TG Therapeutics, Inc. (NASDAQ:TGTX), reported the first presentation of preclinical data on the Company’s novel fully human anti-PD-L1 monoclonal antibody at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting, being held this week, April 1-5, 2017, at the Walter E. Washington Convention Center in Washington, D.C (Press release, TG Therapeutics, APR 4, 2017, View Source [SID1234518469]). Schedule your 30 min Free 1stOncology Demo! The following poster was presented today, April 4, 2017, during the Immunoconjugates and Antibodies Session in Halls A-C.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Preclinical Characterization of a Novel Fully Human lgG1 Anti-PD-L1 mAb CK-301
Based on the various assays performed, the poster concluded:
CK-301 is a high affinity PD-L1 specific fully humanized lgG1 antibody which blocks binding of PD-L1 to PD-1.
Activity of CK-301 in all assays tested was similar to anti-PD-L1’s used as active controls (surrogates of avelumab, atezolizumab, or durvalumab).
Similar to the approved anti-PD-L1, avelumab, CK-301 has the potential to induce ADCC (antibody-dependent cell-mediated cytotoxicity).
A first-in-human Phase 1 study of CK-301 is planned to commence this year.
Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, "The team has worked hard to develop a high quality anti-PD-L1 antibody which we believe is the cornerstone of any proprietary immune-oncology (I/O) strategy. While anti-PD-1/PD-L1 therapy has been broadly explored in solid tumors, we are still in the very early days of understanding their utility and best applications in B-cell malignancies. As a company, we have been highly focused on developing best-in-class combination therapies for patients with B-cell malignancies and believe the next generation of combinations will include both targeted therapies, like TG-1101 and TGR-1202, plus I/O agents like our anti-PD-L1 antibody presented here today. We look forward to commencing the first-in-human study this year."